The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo
Open Access
- 24 July 2008
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 13 (8b) , 2376-2385
- https://doi.org/10.1111/j.1582-4934.2008.00436.x
Abstract
Histone deacetylase (HDAC) inhibitors represent a promising class of antineoplastic agents which affect tumour growth, differentiation and invasion. The effects of the HDAC inhibitor valproic acid (VPA) were tested in vitro and in vivo on pre-clinical renal cell carcinoma (RCC) models. Caki-1, KTC-26 or A498 cells were treated with various concentrations of VPA during in vitro cell proliferation 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays and to evaluate cell cycle manipulation. In vivo tumour growth was conducted in subcutaneous xenograft mouse models. The anti-tumoural potential of VPA combined with low-dosed interferon-α (IFN-α) was also investigated. VPA significantly and dose-dependently up-regulated histones H3 and H4 acetylation and caused growth arrest in RCC cells. VPA altered cell cycle regulating proteins, in particular CDK2, cyclin B, cyclin D3, p21 and Rb. In vivo, VPA significantly inhibited the growth of Caki-1 in subcutaneous xenografts, accompanied by a strong accumulation of p21 and bax in tissue specimens of VPA-treated animals. VPA–IFN-α combination markedly enhanced the effects of VPA monotherapy on RCC proliferation in vitro, but did not further enhance the anti-tumoural potential of VPA in vivo. VPA was found to have profound effects on RCC cell growth, lending support to the initiation of clinical testing of VPA for treating advanced RCC.Keywords
This publication has 32 references indexed in Scilit:
- Enhancing the anti-angiogenic action of histone deacetylase inhibitorsMolecular Cancer, 2007
- Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivoInternational Journal of Urology, 2007
- Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trialBritish Journal of Cancer, 2007
- Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endotheliumBritish Journal of Cancer, 2007
- Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in NeuroblastomaCancer Research, 2007
- Sinusoidal swinging dynamics of the telomere repair and cell growth activation functions of telomerase in rat liver cancer cellsFEBS Letters, 2006
- Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivoCancer Research, 2006
- RNA Interference Suppression of MUC1 Reduces the Growth Rate and Metastatic Phenotype of Human Pancreatic Cancer CellsClinical Cancer Research, 2006
- Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studiesMedicinal Research Reviews, 2005
- Antitumor activity of sodium valproate in cultures of human neuroblastoma cellsAnti-Cancer Drugs, 1996